The Therapeutic Effect of Triple Therapy in Helicobacter pylori Infection

Kim, Boo Sung; Chung, In Sik; Park, Doo Ho; Yang, Young Sang; Lee, Dong Soo; Kim, Sang Woo; Byun, Byung Hun; Choi, Jong Young

Abstract

BACKGROUND AND AIMS: Helicobacter pylori infection is associated with chronic active gastritis, duodenal and gastric ulcers, gastric adenocarcinoma, and gastric lymphoma. Today, eradication of H. pylori represent a generally accepted and beneficial therapeutic strategy for treatment and prevention of peptic ulcer relapse. Major factors that affected on H. pylori eradication are eradication rate of regimen, and compliance of patients. The combination of omeprazole, amoxicillin and clarithromycin has been accepted as one of the most effective treatment for the eradication of H. pylori. The primary aim of this study was to examine the eradication rates of H. pylori infection and side effects of triple therapy in patients with H. pylori infection.
METHODS
Patients were treated with one of two triple therapies, lansoprazole 30 mg BID, clarithromycin 500 mg BID, placebo (LC group) or lansoprazole 30 mg BID, clarithromyein 500 mg BID, amoxicillin 500 mg QID (LCA group), for 14 days.
RESULTS
H. pylori was eradicated in out of 22 patients in LC group (41%) and in 31 out of 38 patients in LCA group (82%). The most frequently observed adverse event was altered taste. Other adverse events included headache and diarrhea.
CONCLUSIONS
Triple therapy with lansoprazole, claritbromycin and amoxicillin for two weeks is an effective and well tolerated regimen for the treatment of H. pylori infection.